Hyperkalemia After Initiating Renin–Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project
Open Access
- 1 July 2017
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American Heart Association
- Vol. 6 (7)
- https://doi.org/10.1161/jaha.116.005428
Abstract
Background: Concerns about hyperkalemia limit the use of angiotensin‐converting enzyme inhibitors ( ACE ‐I) and angiotensin receptor blockers ( ARB s), but guidelines conflict regarding potassium‐monitoring protocols. We quantified hyperkalemia monitoring and risks after ACE ‐I/ ARB initiation and developed and validated a hyperkalemia susceptibility score. Methods and Results: We evaluated 69 426 new users of ACE ‐I/ ARB therapy in the Stockholm Creatinine Measurements ( SCREAM ) project with medication initiation from January 1, 2007 to December 31, 2010, and follow‐up for 1 year thereafter. Three fourths (76%) of SCREAM patients had potassium checked within the first year. Potassium >5 and >5.5 mmol/L occurred in 5.6% and 1.7%, respectively. As a comparison, we propensity‐matched new ACE ‐I/ ARB users to 20 186 new β‐blocker users in SCREAM : 64% had potassium checked. The occurrence of elevated potassium levels was similar between new β‐blocker and ACE ‐I/ ARB users without kidney disease; only at estimated glomerular filtration rate 2 were risks higher among ACE ‐I/ ARB users. We developed a hyperkalemia susceptibility score that incorporated estimated glomerular filtration rate, baseline potassium level, sex, diabetes mellitus, heart failure, and the concomitant use of potassium‐sparing diuretics in new ACE ‐I/ ARB users; this score accurately predicted 1‐year hyperkalemia risk in the SCREAM cohort (area under the curve, 0.845, 95% CI : 0.840–0.869) and in a validation cohort from the US ‐based Geisinger Health System (N=19 524; area under the curve, 0.818, 95% CI : 0.794–0.841), with good calibration. Conclusions: Hyperkalemia within the first year of ACE ‐I/ ARB therapy was relatively uncommon among people with estimated glomerular filtration rate >60 mL/min per 1.73 m 2 , but rates were much higher with lower estimated glomerular filtration rate. Use of the hyperkalemia susceptibility score may help guide laboratory monitoring and prescribing strategies.Keywords
This publication has 32 references indexed in Scilit:
- Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized studyBMC Research Notes, 2013
- Association of Hypo- and Hyperkalemia with Disease Progression and Mortality in Males with Chronic Kidney Disease: The Role of RaceNephron Clinical Practice, 2011
- Predicting the risk of hyperkalemia in patients with chronic kidney disease starting lisinoprilPharmacoepidemiology and Drug Safety, 2010
- The Frequency of Hyperkalemia and Its Significance in Chronic Kidney DiseaseArchives of Internal Medicine, 2009
- Effect of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Serum Potassium Levels and Renal Function in Ambulatory Outpatients: Risk Factors AnalysisThe American Journal of the Medical Sciences, 2008
- Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockersPharmacoepidemiology and Drug Safety, 2006
- Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk PatientsThe New England Journal of Medicine, 2000
- Effect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal InsufficiencyThe New England Journal of Medicine, 1996
- Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart FailureThe New England Journal of Medicine, 1991
- Effect of Captopril on Progressive Ventricular Dilatation after Anterior Myocardial InfarctionThe New England Journal of Medicine, 1988